Nasus Pharma Ltd. has appointed Nir Sassi as its new Chief Financial Officer, effective November 11, 2026. Sassi brings nearly 25 years of experience in capital markets and biopharmaceutical finance to the company as it prepares for a pivotal Phase 3 study of its lead candidate, NS002, in the fourth quarter of 2026.
The appointment of Nir Sassi as CFO, effective November 11, 2026, adds financial leadership with nearly 25 years of experience ahead of the planned NS002 Phase 3 study initiation in Q4 2026 and topline readout in Q1 2027. However, the release contains no hard financial figures, guidance change or clinical result, so it does not materially alter the investment case. The pipeline milestones cited are already stated plans, not new data.
- • NS002 pivotal Phase 3 study planned to start in Q4 2026
- • Topline data readout expected Q1 2027
- • Phase 3 timing and outcomes remain uncertain
- • Company may need additional financing, as noted in the forward-looking statements